- Home
- KOD vs NHS Comparison
KOD vs NHS Comparison
Compare KOD & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- NHS
- Stock Information
- Founded
- KOD 2009
- NHS 2003
- Country
- KOD United States
- NHS United States
- Employees
- KOD N/A
- NHS N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- NHS Trusts Except Educational Religious and Charitable
- Sector
- KOD Health Care
- NHS Finance
- Exchange
- KOD Nasdaq
- NHS Nasdaq
- Market Cap
- KOD 188.9M
- NHS 221.6M
- IPO Year
- KOD 2018
- NHS N/A
- Fundamental
- Price
- KOD $3.62
- NHS $7.55
- Analyst Decision
- KOD Hold
- NHS
- Analyst Count
- KOD 3
- NHS 0
- Target Price
- KOD $9.00
- NHS N/A
- AVG Volume (30 Days)
- KOD 294.1K
- NHS 111.8K
- Earning Date
- KOD 08-13-2025
- NHS 01-01-0001
- Dividend Yield
- KOD N/A
- NHS 13.44%
- EPS Growth
- KOD N/A
- NHS N/A
- EPS
- KOD N/A
- NHS N/A
- Revenue
- KOD N/A
- NHS N/A
- Revenue This Year
- KOD N/A
- NHS N/A
- Revenue Next Year
- KOD N/A
- NHS N/A
- P/E Ratio
- KOD N/A
- NHS N/A
- Revenue Growth
- KOD N/A
- NHS N/A
- 52 Week Low
- KOD $1.92
- NHS $6.95
- 52 Week High
- KOD $11.60
- NHS $9.17
- Technical
- Relative Strength Index (RSI)
- KOD 46.82
- NHS 51.22
- Support Level
- KOD $3.52
- NHS $7.54
- Resistance Level
- KOD $3.78
- NHS $7.71
- Average True Range (ATR)
- KOD 0.35
- NHS 0.06
- MACD
- KOD -0.05
- NHS 0.00
- Stochastic Oscillator
- KOD 30.77
- NHS 53.57
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.